Essex Bio-Technology (HK:1061) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Essex Bio-Technology Limited has announced that its subsidiary, Zhuhai Essex Bio-Pharmaceutical Company Limited, has gained approval from China’s National Medical Products Administration to commercialize a new preservative-free unit-dose Diquafosol Sodium Eye Drop for treating dry eye syndromes. This product adds to the company’s existing portfolio of preservative-free eye treatments, indicating a potential expansion in the PRC’s healthcare market.
For further insights into HK:1061 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue